FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3092996287> ?p ?o ?g. }

• W3092996287 endingPage "1264" @default.
• W3092996287 startingPage "1248" @default.
• W3092996287 abstract "To conduct a systematic review and meta-analysis investigating the effect of tofacitinib and baricitinib on venous thromboembolism (VTE) risk. Search of PubMed, EMBASE, Web of Science, Scopus, ClinicalTrials.gov, LILACS, and Google Scholar databases to identify controlled observational and clinical trials reporting on adverse effects in patients treated with oral tofacitinib or baricitinib up to July 2020. The outcome measure was occurrence of VTE events. We analyzed 59 studies involving 14,335 patients treated with tofacitinib or baricitinib and 11,612 patients who received another active drug or placebo. The meta-analysis showed an odds ratio (OR) for VTE events of 0.29 (95% confidence interval [CI] = 0.10-0.84) overall for tofacitinib based on data from 10 clinical trials with 15 treatment arms; similar ORs were observed for the 10 mg/d dose (OR = 0.18; 95% CI = 0.02-1.60) and the 20 mg/d dose (OR = 0.19; 95% CI = 0.04-0.91). The ORs for VTE events for baricitinib were 3.39 (95% CI = 0.82-14.04) overall, 3.05 (95% CI = 0.12-75.43) for 2 mg, 3.64 (95% CI = 0.59-22.46) for 4 mg, and 3.0 (95% CI = 0.12-76.49) for 7 mg. The indirect meta-analysis comparing tofacitinib with baricitinib (10 clinical trials with 15 treatment arms) showed an OR for VTE events of 0.086 (95% CI = 0.02-0.51) for tofacitinib and a superior safety profile for VTE events. In the meta-regression analysis (19 clinical trials with 21 treatment arms), the effect was 0.02 (95% CI = -0.04 to 0.08) for tofacitinib and -0.01 (95% CI = -1.29 to 1.26 for baricitinib. Plotting of the data for tofacitinib showed that VTE risk increased with high doses. The effect, however, was less than 1 for the 10-mg and 20-mg doses, indicating a protective effect. This effect was not observed for baricitinib. Tofacitinib is not associated with an increased risk of VTE and has a superior safety profile to baricitinib in this respect. Tofacitinib may exert a protective effect against VTE." @default.
• W3092996287 created "2020-10-22" @default.
• W3092996287 creator A5027316964 @default.
• W3092996287 creator A5044340812 @default.
• W3092996287 creator A5067900775 @default.
• W3092996287 date "2020-11-16" @default.
• W3092996287 modified "2023-09-25" @default.
• W3092996287 title "Risk of Venous Thromboembolism Associated With Tofacitinib and Baricitinib: A Systematic Review and Indirect Meta‐Analysis" @default.
• W3092996287 cites W1596902544 @default.
• W3092996287 cites W1881640566 @default.
• W3092996287 cites W1892175722 @default.
• W3092996287 cites W1974321634 @default.
• W3092996287 cites W1990105300 @default.
• W3092996287 cites W1991688187 @default.
• W3092996287 cites W2014330392 @default.
• W3092996287 cites W2035320881 @default.
• W3092996287 cites W2038992287 @default.
• W3092996287 cites W2069302785 @default.
• W3092996287 cites W2069871920 @default.
• W3092996287 cites W2074439189 @default.
• W3092996287 cites W2097302763 @default.
• W3092996287 cites W2101217991 @default.
• W3092996287 cites W2123414080 @default.
• W3092996287 cites W2138609584 @default.
• W3092996287 cites W2138647255 @default.
• W3092996287 cites W2139672588 @default.
• W3092996287 cites W2149447280 @default.
• W3092996287 cites W2153414586 @default.
• W3092996287 cites W2164858045 @default.
• W3092996287 cites W2167305078 @default.
• W3092996287 cites W2254470680 @default.
• W3092996287 cites W2311909212 @default.
• W3092996287 cites W2312279372 @default.
• W3092996287 cites W2329371764 @default.
• W3092996287 cites W2525212149 @default.
• W3092996287 cites W2530335997 @default.
• W3092996287 cites W2531269403 @default.
• W3092996287 cites W2554626374 @default.
• W3092996287 cites W2587875644 @default.
• W3092996287 cites W2588044396 @default.
• W3092996287 cites W2611548364 @default.
• W3092996287 cites W2616575727 @default.
• W3092996287 cites W2626892937 @default.
• W3092996287 cites W2749941863 @default.
• W3092996287 cites W2766717228 @default.
• W3092996287 cites W2766846920 @default.
• W3092996287 cites W2767394258 @default.
• W3092996287 cites W2778484302 @default.
• W3092996287 cites W2790867818 @default.
• W3092996287 cites W2883700530 @default.
• W3092996287 cites W2905169896 @default.
• W3092996287 cites W2916179527 @default.
• W3092996287 cites W2945228415 @default.
• W3092996287 cites W2970684805 @default.
• W3092996287 cites W2995154511 @default.
• W3092996287 cites W3000133404 @default.
• W3092996287 cites W3003334583 @default.
• W3092996287 doi "https://doi.org/10.1002/phar.2472" @default.
• W3092996287 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33064892" @default.
• W3092996287 hasPublicationYear "2020" @default.
• W3092996287 type Work @default.
• W3092996287 sameAs 3092996287 @default.
• W3092996287 citedByCount "16" @default.
• W3092996287 countsByYear W30929962872021 @default.
• W3092996287 countsByYear W30929962872022 @default.
• W3092996287 crossrefType "journal-article" @default.
• W3092996287 hasAuthorship W3092996287A5027316964 @default.
• W3092996287 hasAuthorship W3092996287A5044340812 @default.
• W3092996287 hasAuthorship W3092996287A5067900775 @default.
• W3092996287 hasConcept C126322002 @default.
• W3092996287 hasConcept C141071460 @default.
• W3092996287 hasConcept C17744445 @default.
• W3092996287 hasConcept C177713679 @default.
• W3092996287 hasConcept C189708586 @default.
• W3092996287 hasConcept C199539241 @default.
• W3092996287 hasConcept C2777575956 @default.
• W3092996287 hasConcept C2778886723 @default.
• W3092996287 hasConcept C2779473830 @default.
• W3092996287 hasConcept C2780868729 @default.
• W3092996287 hasConcept C2991741193 @default.
• W3092996287 hasConcept C71924100 @default.
• W3092996287 hasConcept C95190672 @default.
• W3092996287 hasConceptScore W3092996287C126322002 @default.
• W3092996287 hasConceptScore W3092996287C141071460 @default.
• W3092996287 hasConceptScore W3092996287C17744445 @default.
• W3092996287 hasConceptScore W3092996287C177713679 @default.
• W3092996287 hasConceptScore W3092996287C189708586 @default.
• W3092996287 hasConceptScore W3092996287C199539241 @default.
• W3092996287 hasConceptScore W3092996287C2777575956 @default.
• W3092996287 hasConceptScore W3092996287C2778886723 @default.
• W3092996287 hasConceptScore W3092996287C2779473830 @default.
• W3092996287 hasConceptScore W3092996287C2780868729 @default.
• W3092996287 hasConceptScore W3092996287C2991741193 @default.
• W3092996287 hasConceptScore W3092996287C71924100 @default.
• W3092996287 hasConceptScore W3092996287C95190672 @default.
• W3092996287 hasIssue "12" @default.
• W3092996287 hasLocation W30929962871 @default.
• W3092996287 hasOpenAccess W3092996287 @default.

• next